Kasturi Haldar and col leagues from Northwestern University Medical School, Chicago, investigated a protein in red blood cells (erythrocyte guanine nucleotide regulatory protein Gs) as a novel antimalarial target. They showed that a commonly used antihypertensive drug, propranolol, decreased Gs activity in red blood cells and inhibited blood-stage malarial parasite growth, as did other drugs of the same class. When used in combination with existing antimalarials in cell culture, propranolol reduced the dose of existing antimalarial drugs required to treat animal models of malarial infection. Erythrocyte G may therefore be a novel antimalarial target; in addition, drugs antagonising erythrocyte Gs could be used in combination therapies with existing antimalarial drugs.
Citation: Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, et al. (2006) Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med 3(12): e528.
PLEASE ADD THE LINK TO THE PUBLISHE D ARTICLE IN ONLINE VERSIONS OF YOU R REPORT:
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030528
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-haldar.pdf
Related image for press use: http://www.plos.org/press/plme-03-12-haldar.jpg
- Caption: Erythrocyte G protein signaling is needed for intracellular malarial parasite proliferation and thus may present a novel antimalarial target (Photographer: Sean C. Murphy)
CONTACTS:
Kasturi Haldar
Northwestern University Medical School
Department of Pathology and Microbiology-Immunology
Ward Bldg. 3rd Floor Rm 220
303 E. Chicago Ave
Chicago, IL 60611-3008 United States of America
+1 312-503-0224
+1 312-503-8240 (fax)
k-haldar@northwestern.edu
Sean Murphy
Northwestern University
Department of Pathology
303 E. Chicago Avenue
Ward 3-240
Chicago, IL 60611
+1 312-503-1443
+1 312-503-0281 (fax)
sean-murphy@md.northwestern.edu
THE FOLLOWING RESEARCH ARTICLES WILL ALSO BE PUBLISHED ONLINE:
Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants
Experiments in mice suggest challenges in vaccine design for controlling future SARS-CoV zoonosis, especially in vulnerable elderly populations.
Citation: Deming D, Sheahan T, Heise M, Yount B, Davis N, et al. (2006) Vaccine efficacy in senescen t mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 3(12): e525.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPO RT:
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030525
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-baric.pdf
CONTACT:
Ralph Baric
University of North Carolina
Epidemiology
3304 Hooker Research Building
School of Public Health
Chapel Hill, North Carolina 27599-7435
+1 919-966-3895
+1 919-966-2089 (fax)
ralph_baric@unc.edu
A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies
Citation: Shames DS, Girard L, Gao B, Sato M, Lewis CM, et al. (2006) A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3(12): e486.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT:
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030486
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-minna.pdf
CONTACT:
John Minna
Southwestern Medical Center at Dallas
Hamon Center for Therapeutic Oncology Research
Hamon Center for Therapeutic Oncology Research University of Texas Southwestern Medical Center Building NB8-206
6000 Harry Hines Boulevard
Dallas, TX 75390-8590
+1 214-648-4900
+1 214-648-4940 (fax)
john.minna@utsouthwestern.edu
A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer
Citation: Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, et al. (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3(12): e467.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT:
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.003 0467
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-you.pdf
CONTACT:
Ming You
Washington University
Department of Surgery
660 S Euclid Ave
St Louis, MO 63110
+1-314-262-9294
youm@wustl.edu
Angiotensin-Converting Enzyme I/D Polymorphism and Preeclampsia Risk: Evidence of Small-Study Bias
The observed small increase in risk of preeclampsia associated with the ACE D-allele is likely to be due to small-study bias, a similar result to that observed in cardiovascular disease.
Citation: Serrano NC, DÃaz LA, Páez MC, Mesa CM, Cifuentes R, et al. (2006) Angiotensin-converting enzyme insertion/deletion polymorphism and preeclampsia risk: Evidence of small-study bias . PLoS Med 3(12): e520.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT:
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030520
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-casas.pdf
CONTACT:
Juan Pablo Casas
London School of Hygiene & Tropical Medicine
Epidemiology and Population Health
Keppel Street
London WC1E 7HT
+44 207 927 2163
Juan.Pablo-Casas@lshtm.ac.uk
Lipoprotein Particle Profiles Mark Familial and Sporadic Human Longevity
Offspring of families from the Leiden Longevity Study had larger and fewer LDL particles than same-aged partners, suggesting that even in middle age LDL particle profiles are associated with longevity.
Citation: Heijmans BT, Beekman M, Houwing-Duistermaat JJ, Cobain MR, Powell J, et al. (2006) Lipoprotein particle profiles mark familial and sporadic human longevity. PLoS Med 3(12): e495.
PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE VERSIONS OF YOUR REPORT:
http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030495
PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-03-12-heijmans.pdf
CONTACT:
Bastiaan Heijmans
Leiden University Medical Centre
Molecular Epidemiology
Postal Zone S-05-P
PO Box 9600
Leiden, Zuid-Holland 2300 RC Nether lands
+31 71 5271914
b.t.heijmans@lumc.nl
EMBARGO: MONDAY, 25 December, 5 P.M. PST
PLEASE MENTION THE OPEN-ACCESS JOURNAL PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES AND PROVIDE A LINK TO THE FREELY-AVAILABLE TEXT. THANK YOU.
All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere to read, download, redistribute, include in databases, and otherwise use subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org
Journal
PLoS Medicine